10506-73-7 Usage
Synthetic estrogen compound
16-methylene estrone is a synthetic compound that is structurally similar to the natural hormone estrone.
Research purposes
It is primarily used for research purposes and has been studied for its potential therapeutic effects.
Treating conditions related to estrogen imbalance
It has been studied for its potential therapeutic effects in treating conditions related to estrogen imbalance, such as hormone-dependent cancers and menopausal symptoms.
Anti-proliferative and anti-estrogenic properties
16-methylene estrone has been found to exhibit anti-proliferative and anti-estrogenic properties, making it a potential candidate for hormone therapy.
Binding to estrogen receptors
Its unique chemical structure enables it to bind to estrogen receptors and modulate estrogen signaling pathways.
Check Digit Verification of cas no
The CAS Registry Mumber 10506-73-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,0,5,0 and 6 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 10506-73:
(7*1)+(6*0)+(5*5)+(4*0)+(3*6)+(2*7)+(1*3)=67
67 % 10 = 7
So 10506-73-7 is a valid CAS Registry Number.
InChI:InChI=1/C19H22O2/c1-11-9-17-16-5-3-12-10-13(20)4-6-14(12)15(16)7-8-19(17,2)18(11)21/h4,6,10,15-17,20H,1,3,5,7-9H2,2H3/t15-,16-,17+,19+/m1/s1
10506-73-7Relevant articles and documents
Potent anti-ovarian cancer with inhibitor activities on Both Topoisomerase II and V600EBRAF of synthesized substituted estrone candidates
El-Naggar, Mohamed,Amr, Abd El-Galil E.,Fayed, Ahmed A.,Elsayed, Elsayed A.,Al-Omar, Mohamed A.,Abdalla, Mohamed M.
, (2019)
A series of 16-(α-alkoxyalkane)-17-hydrazino-estra-1(10),2,4-trien[17,16-c]-3-ol (3a-l) and estra-1(10),2,4-trien-[17,16-c]pyrazoline-3-ol derivatives (4a-d) were synthesized from corresponding arylidines 2a,b which was prepared from estrone 1 as starting material. Condensation of 1 with aldehydes gave the corresponding arylidine derivatives 2a,b which were treated with hydrazine derivatives in alcohols to give the corresponding derivatives 3a-l, respectively. Additionally, treatment of 2a,b with methyl- or phenylhydrazine in ethanolic potassium hydroxide afforded the corresponding N-substituted pyrazoline derivatives 4a-d, respectively. All these derivatives showed potent anti-ovarian cancer both in vitro and in vivo. The mechanism of anti-ovarian cancer was suggested to process via topoisomerase II and V600EBRAF inhibition.
